IRADIMED Reports Strong 2025 Results with 14.4% Revenue Growth, Increased Dividend, and New Product Launch
IRMD has more than doubled off its 52-week low of $47.478.
Summary
IRADIMED CORPORATION reported robust financial results for fiscal year 2025, including a 14.4% increase in revenue and a 17.6% hike in its quarterly cash dividend, alongside the successful launch of its new MRidium 3870 IV infusion pump system.
Key Events · Earnings and Guidance · IRMD
-
Strong Financial Performance
Achieved $83.8 million in revenue for 2025, a 14.4% increase year-over-year from $73.2 million in 2024. Diluted EPS rose to $1.75 in 2025 from $1.50 in 2024.
-
Increased Quarterly Dividend
The Board of Directors declared an increased regular quarterly cash dividend of $0.20 per share in February 2026, up from $0.17, reflecting confidence in future cash flows.
-
New Product Introduction
Successfully launched the MRidium 3870 MRI Compatible IV Infusion Pump System in 2025, with initial customer shipments in December 2025, enhancing its product portfolio.
-
New Manufacturing Facility Completed
Completed and occupied a new 62,000 square foot corporate office and manufacturing facility in Orlando, Florida, in Q3 2025, funded entirely with cash.
Analysis · IRMD · Industrial Applications And Services
This 10-K filing highlights IRADIMED's strong operational and financial execution in 2025. The significant revenue and EPS growth, coupled with a substantial increase in the quarterly dividend, signals management's confidence in the company's sustained performance and cash generation capabilities. The introduction of the next-generation MRidium 3870 infusion pump and the completion of the new, cash-funded manufacturing facility are key strategic achievements that position the company for continued innovation and growth in its specialized MRI-compatible medical device market. While the CEO's 10b5-1 plan involved some share sales, it was pre-planned and has concluded, and the amount was minor relative to the company's market capitalization. Investors should view this report as a positive indicator of the company's trajectory and commitment to shareholder returns.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IRMD was trading at $98.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $47.48 to $107.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.